Newsletter | 01 February 2003 Access News 8, Focus on Access Three Years On, February 2003 HIV/AIDS RESEARCH AND DEVELOPMENT TROPICAL & NEGLECTED DISEASES VACCINES The Access Campaign three years on is addressed in this issue of AccessNews, as well as the fear of another meningitis epidemic, Roche's failing of HIV patients, fighting against neglected diseases, no agreements at Doha and HIV positive children. Read, watch, share Filter by - Any -BlogEventsFeature storyInfographicInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechStatementTechnical briefTopic overviewVideo Press release Press release | 30 March 2026 HIV/AIDS Gilead refuses to sell groundbreaking HIV prevention drug to MSF Photo credit: Jan-Joseph Stok Press release Press release | 26 September 2025 HIV/AIDS MSF Supports $40 PrEP Access by 2027, Demands Broader Reach and more Ambition to End HIV Epidemic 3 min Technical brief | 03 July 2025 HIV/AIDS Intellectual property and trade Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access Copyright: Stefan Heunis Press release Press release | 15 May 2025 HIV/AIDS Tuberculosis South AfricaUnited States of America US funding cuts threaten 39 research sites in South Africa, putting scientific advancements and hard-won progress against TB and HIV at risk 5 min Report | 15 May 2025 HIV/AIDS Research and development South AfricaUnited States of America South Africa’s TB and HIV Research at Risk : A Call To Catalyze Urgent Action By Funders Photo Credit: Martim Gray Pereira/MSF Press release Press release | 14 February 2025 HIV/AIDS United States of America Uncertainty around PEPFAR program puts millions of people at risk 6 min Technical brief | 04 September 2024 HIV/AIDS Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit Research article | 16 August 2024 HIV/AIDS Lancet HIV: The long wait for long-acting HIV prevention and treatment formulations Load More
Press release Press release | 30 March 2026 HIV/AIDS Gilead refuses to sell groundbreaking HIV prevention drug to MSF
Photo credit: Jan-Joseph Stok Press release Press release | 26 September 2025 HIV/AIDS MSF Supports $40 PrEP Access by 2027, Demands Broader Reach and more Ambition to End HIV Epidemic 3 min
Technical brief | 03 July 2025 HIV/AIDS Intellectual property and trade Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access
Copyright: Stefan Heunis Press release Press release | 15 May 2025 HIV/AIDS Tuberculosis South AfricaUnited States of America US funding cuts threaten 39 research sites in South Africa, putting scientific advancements and hard-won progress against TB and HIV at risk 5 min
Report | 15 May 2025 HIV/AIDS Research and development South AfricaUnited States of America South Africa’s TB and HIV Research at Risk : A Call To Catalyze Urgent Action By Funders
Photo Credit: Martim Gray Pereira/MSF Press release Press release | 14 February 2025 HIV/AIDS United States of America Uncertainty around PEPFAR program puts millions of people at risk 6 min
Technical brief | 04 September 2024 HIV/AIDS Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit
Research article | 16 August 2024 HIV/AIDS Lancet HIV: The long wait for long-acting HIV prevention and treatment formulations
